ASAM Guidelines on Benzodiazepine Tapering Workshop

Holiday Special!
Through the holidays, access the ASAM Guidelines on Benzodiazepine Tapering Workshop for just $300 (regularly $385)!

Benzodiazepine tapering remains a complex and often nuanced aspect of addiction medicine. This session will provide a structured overview of the American Society of Addiction Medicine (ASAM) guidelines for benzodiazepine tapering, offering clinicians evidence-based tools to support safe, individualized treatment plans. While the session will begin with a robust educational segment to orient attendees to the key principles and recommendations outlined in the guidelines, it will also feature audience-interactive components, including small group discussions and real-world case challenges. Attendees will be invited to share difficult patient scenarios in advance or during the session, fostering peer learning and practical application of tapering strategies. Topics will include patient selection, risk stratification, tapering protocols, management of withdrawal symptoms, and alternative approaches for anxiety and insomnia.

Speaker(s):

  • Mason Turner, MD, DFASAM  -  Senior Medical Director, Enterprise, Behavioral Health Clinical Program, Intermountain Health
  • Tiffany Lu, MD, MS  -  Associate Medical Director of Addiction Services, New York City Health & Hospitals/Jacobi
  • Stephen Leung, MD  -  Assistant Professor, Psychiatry, UCSF School of Medicine
  • Donovan Maust, MD, MS  -  Research Professor in Geriatric Psychiatry; Associate Director, Ann Arbor VA Center for Clinical Management Research
  • David Dadiomov, PharmD, BCPP  -  Assistant Professor of Clinical Pharmacy; Director, PGY2 Psychiatric Pharmacy Program, Titus Family Department of Clinical Pharmacy

 

 

Learning Objectives

  • Apply key clinical takeaways and strategies for safely tapering benzodiazepines as outlined in the Joint Clinical Practice Guideline on Benzodiazepine Tapering.  
  • Differentiate between benzodiazepine physical dependence and benzodiazepine use disorder when developing individualized care plans. 
  • Conduct risk-benefit assessments to inform tapering strategies and implement close monitoring and adjustments based on a patient’s response during tapering.  
  • Individualize benzodiazepine tapering strategies for patients with co-occurring mental health conditions.
  • Describe benzodiazepine pharmacology and pharmacokinetics relevant to clinical use and tapering.
 
 
    Course summary
    Available credit: 
    • 3.00 AMA Category 1
    • 3.00 Attendance
    Course opens: 
    11/01/2025
    Course expires: 
    10/02/2026
    Cost:
    $200.00

     

    • Mason Turner, MD, DFASAM  -  Senior Medical Director, Enterprise, Behavioral Health Clinical Program, Intermountain Health
    • Tiffany Lu, MD, MS  -  Associate Medical Director of Addiction Services, New York City Health & Hospitals/Jacobi
    • Stephen Leung, MD  -  Assistant Professor, Psychiatry, UCSF School of Medicine
    • Donovan Maust, MD, MS  -  Research Professor in Geriatric Psychiatry; Associate Director, Ann Arbor VA Center for Clinical Management Research
    • David Dadiomov, PharmD, BCPP  -  Assistant Professor of Clinical Pharmacy; Director, PGY2 Psychiatric Pharmacy Program, Titus Family Department of Clinical Pharmacy

    PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the California Medical Association to provide continuing medical education for physicians.  CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

    CSAM designates this educational activity/enduring material for a maximum of 3 AMA/PRA Category 1 Credits™. (Physicians should only claim credit commensurate with the extent of their participation in the activity.) This credit may also be applied to the CMA Certification in Continuing Medical Education.

    NON-PHYSICIANS: The California Society of Addiction Medicine (CSAM) provides a certificate of attendance for this online course based upon the number of hours you participated, up to maximum of 3. 

    DISCLOSURE OF FINANCIAL RELATIONSHIPS

    In accordance with the ACCME Standards for Integrity and Independence, CSAM adheres to guidelines and processes to identify and mitigate relevant financial relationships for all individuals in a position to control the content of this activity. Unless otherwise noted, faculty did not have any relevant financial relationships with ineligible companies, as defined by ACCME, within the past 24 months. All relevant financial relationships have been mitigated.

    Available Credit

    • 3.00 AMA Category 1
    • 3.00 Attendance

    Price

    Cost:
    $200.00
    Please login or register to take this course.